Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Neurosciences Institute

Neither a doctor nor a teaching hospital

Research payments

$1,446,612

129 payments

Through program year 2025, Advanced Neurosciences Institute is reported as receiving $1,446,612 in research payments, across 129 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $211,806 2
2024 Research $18,894 1
2023 Research $46,606 1
2022 Research $71,423 7
2021 Research $198,468 28
2020 Research $559,469 44
2019 Research $339,947 46

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $427,322 53 payments
  2. Celgene Corporation $345,354 6 payments
  3. Novartis Pharmaceuticals Corporation $174,077 6 payments
  4. Alkermes, Inc. $160,266 29 payments
  5. Biogen, Inc. $126,918 3 payments
  6. E.R. Squibb & Sons, L.L.C. $93,681 1 payment
  7. Janssen Research & Development, LLC $68,208 24 payments
  8. Genentech, Inc. $39,663 5 payments
  9. F. Hoffmann-La Roche AG $11,123 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) $277,306 4 payments
  2. M18-918 $235,269 19 payments
  3. A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis $122,155 3 payments
  4. A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 $117,568 24 payments
  5. A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 $114,181 2 payments
  6. M14-397 $109,456 20 payments
  7. A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) (BMS Study Number: IM047-P46) $81,701 1 payment
  8. Long Term Prospective Multinational Parallel Cohort Study Monitoring Safety in Patients With Multiple Sclerosis Newly Started With Fingolimod Once Daily Or Treated With Another Approved Disease Modifying Therapy $51,922 3 payments
  9. A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing Forms of Multiple Sclerosis $48,792 7 payments
  10. A Multicenter, Longitudinal, Open-Label, Single-Ar $46,618 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record